Twist Bioscience (TWST) Cash from Financing Activities (2017 - 2026)

Twist Bioscience (TWST) has reported Cash from Financing Activities for 10 consecutive years, with $3.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cash from Financing Activities rose 107.39% year-over-year to $3.8 million in Q2 2026; TTM through Jun 2026 was $13.8 million, a 48.12% decrease from a year earlier, with the FY2025 full-year figure at $28.5 million, up 314.22% from the prior year.
• Cash from Financing Activities was $3.8 million for Q2 2026 at Twist Bioscience, down from $4.1 million in the prior quarter.
• Over five years, Cash from Financing Activities peaked at $271.6 million in Q1 2022 and troughed at -$1.5 million in Q4 2023.
• A 5-year average of $17.6 million and a median of $1.8 million in 2024 frame the typical range for Cash from Financing Activities.
• Across the five-year window, Cash from Financing Activities surged 18619.23% in 2022 and tumbled 272.91% in 2023, its largest moves.
• Over 5 years, Cash from Financing Activities stood at -$395000.0 in 2022, then plunged by 272.91% to -$1.5 million in 2023, then surged by 1318.19% to $17.9 million in 2024, then plunged by 98.34% to $298000.0 in 2025, then soared by 1170.81% to $3.8 million in 2026.
• The last three Cash from Financing Activities figures came in at $3.8 million (Q2 2026), $4.1 million (Q1 2026), and $298000.0 (Q4 2025), per Business Quant data.